$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby

$nby Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000143774917005131 Filed on March 23, 2017

Income Statement

Concept	2015 Q4	2014 Q4	2014
Revenue	$1.640M	$490.0K	$1.054M
YoY Change	234.69%	-3.92%	-69.71%
Cost Of Revenue	$590.0K	$300.0K	$486.0K
YoY Change	96.67%	275.0%	203.75%
Gross Profit	$1.040M	$190.0K	$568.0K
YoY Change	447.37%	-55.81%	-82.89%
Gross Profit Margin	63.41%	38.78%	53.89%
Selling, General & Admin	$5.950M	$2.660M	$7.989M
YoY Change	123.68%	111.11%	26.01%
% of Gross Profit	572.12%	1400.0%	1406.51%
Research & Development	$1.240M	$2.430M	$9.483M
YoY Change	-48.97%	-39.85%	-23.89%
% of Gross Profit	119.23%	1278.95%	1669.54%
Depreciation & Amortization	$40.00K	$40.00K	$232.0K
YoY Change	0.0%	-42.86%	-25.16%
% of Gross Profit	3.85%	21.05%	40.85%
Operating Expenses	$7.190M	$5.090M	$17.47M
YoY Change	41.26%	-3.96%	-7.06%
Operating Profit	-$6.150M	-$4.900M	-$16.90M
YoY Change	25.51%	0.62%	9.2%
Interest Expense	$1.980M	$450.0K	$1.664M
YoY Change	340.0%	-38.36%	-397.14%
% of Operating Profit
Other Income/Expense, Net	-$30.00K	-$30.00K	$48.00K
YoY Change	0.0%	200.0%
Pretax Income	-$4.200M	-$4.480M	-$15.19M
YoY Change	-6.25%	7.95%	-5.29%
Income Tax	$0.00	-$10.00K	$2.000K
% Of Pretax Income
Net Earnings	-$4.200M	-$4.470M	-$15.19M
YoY Change	-6.04%	7.97%	-5.27%
Net Earnings / Revenue	-256.1%	-912.24%	-1441.56%
Basic Earnings Per Share			-$7.65
Diluted Earnings Per Share	-$1.257M	-$2.170M	-$7.65
COMMON SHARES
Basic Shares Outstanding			1.985M
Diluted Shares Outstanding			1.985M

Balance Sheet

Concept	2015 Q4	2014 Q4	2014
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.390M	$5.430M	$5.429M
YoY Change	-55.99%	-58.39%	-58.4%
Cash & Equivalents	$2.385M	$5.429M	$5.429M
Short-Term Investments
Other Short-Term Assets	$261.0K	$730.0K	$729.0K
YoY Change	-64.25%	1.39%	1.25%
Inventory	$1.345M	$520.0K	$521.0K
Prepaid Expenses	$261.0K
Receivables	$540.0K	$270.0K	$273.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$4.527M	$6.950M	$6.952M
YoY Change	-34.86%	-53.01%	-53.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$395.0K	$440.0K	$436.0K
YoY Change	-10.23%	-38.89%	-39.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$155.0K	$150.0K	$149.0K
YoY Change	3.33%	7.14%	6.43%
Total Long-Term Assets	$550.0K	$590.0K	$585.0K
YoY Change	-6.78%	-31.4%	-31.98%
TOTAL ASSETS
Total Short-Term Assets	$4.527M	$6.950M	$6.952M
Total Long-Term Assets	$550.0K	$590.0K	$585.0K
Total Assets	$5.077M	$7.540M	$7.537M
YoY Change	-32.67%	-51.82%	-51.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.483M	$1.870M	$1.865M
YoY Change	32.78%	11.98%	11.68%
Accrued Expenses	$1.980M	$1.060M	$1.055M
YoY Change	86.79%	-34.57%	-34.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.633M	$3.350M	$3.345M
YoY Change	38.3%	-7.71%	-7.85%
LONG-TERM LIABILITIES
Long-Term Debt	$1.660M	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$2.340M	$2.344M
YoY Change		-33.33%	-33.22%
Total Long-Term Liabilities	$0.00	$2.340M	$2.344M
YoY Change	-100.0%	-33.33%	-33.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.633M	$3.350M	$3.345M
Total Long-Term Liabilities	$0.00	$2.340M	$2.344M
Total Liabilities	$10.18M	$5.690M	$5.689M
YoY Change	78.82%	-20.2%	-20.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$90.52M
YoY Change
Common Stock	$35.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$5.098M	$1.848M	$1.848M
YoY Change
Total Liabilities & Shareholders Equity	$5.077M	$7.540M	$7.537M
YoY Change	-32.67%	-51.82%	-51.84%

Cashflow Statement

Concept	2015 Q4	2014 Q4	2014
OPERATING ACTIVITIES
Net Income	-$4.200M	-$4.470M	-$15.19M
YoY Change	-6.04%	7.97%	-5.27%
Depreciation, Depletion And Amortization	$40.00K	$40.00K	$232.0K
YoY Change	0.0%	-42.86%	-25.16%
Cash From Operating Activities	-$4.490M	-$4.140M	-$15.06M
YoY Change	8.45%	-11.54%	16.08%
INVESTING ACTIVITIES
Capital Expenditures	-$70.00K	-$10.00K	$68.00K
YoY Change	600.0%	-90.0%	-148.57%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.270M	$0.00
YoY Change	-100.0%	-4.51%	-100.0%
Cash From Investing Activities	-$80.00K	$1.270M	$2.598M
YoY Change	-106.3%	3.25%	84.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.900M		$227.0K
YoY Change			-97.47%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.570M	420.0K	7.386M
YoY Change	750.0%	-94.02%	-20.84%
NET CHANGE
Cash From Operating Activities	-4.490M	-4.140M	-15.06M
Cash From Investing Activities	-80.00K	1.270M	2.598M
Cash From Financing Activities	3.570M	420.0K	7.386M
Net Change In Cash	-1.000M	-2.450M	-5.071M
YoY Change	-59.18%	-168.63%	127.4%
FREE CASH FLOW
Cash From Operating Activities	-$4.490M	-$4.140M	-$15.06M
Capital Expenditures	-$70.00K	-$10.00K	$68.00K
Free Cash Flow	-$4.420M	-$4.130M	-$15.12M
YoY Change	7.02%	-9.83%	17.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Trading Symbol TradingSymbol	nby
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15288175
CY2016Q2	dei	Entity Public Float EntityPublicFloat	7530005
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016	dei	Entity Registrant Name EntityRegistrantName	NOVABAY PHARMACEUTICALS, INC.
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001389545
CY2016Q3	nby	Class Of Warrants Or Rights Exercises In Period ClassOfWarrantsOrRightsExercisesInPeriod	3613284
CY2016Q4	nby	Class Of Warrants Or Rights Exercises In Period ClassOfWarrantsOrRightsExercisesInPeriod	363523
CY2016	nby	Class Of Warrants Or Rights Exercises In Period ClassOfWarrantsOrRightsExercisesInPeriod	3977
CY2014	nby	Fixed Assets Exchanged For Services FixedAssetsExchangedForServices
CY2016	nby	Gain Loss Due To Change In Fair Value Of Warrant GainLossDueToChangeInFairValueOfWarrant	-2099000
CY2015	nby	Gain Loss Due To Change In Fair Value Of Warrant GainLossDueToChangeInFairValueOfWarrant	2149000
CY2014	nby	Gain Loss Due To Change In Fair Value Of Warrant GainLossDueToChangeInFairValueOfWarrant	1664000
CY2016	nby	Income Tax Reconciliation Iso Related Expense For Gaap IncomeTaxReconciliationISORelatedExpenseForGAAP	52000
CY2015	nby	Income Tax Reconciliation Iso Related Expense For Gaap IncomeTaxReconciliationISORelatedExpenseForGAAP	164000
CY2014	nby	Income Tax Reconciliation Iso Related Expense For Gaap IncomeTaxReconciliationISORelatedExpenseForGAAP	144000
CY2014Q1	nby	Common Stock Shares Per Unit CommonStockSharesPerUnit	1
CY2015	nby	Equity Transferred To Warrant Liability In Shares EquityTransferredToWarrantLiabilityInShares	-2175000
CY2016	nby	Fair Market Value Of Warrants Transferred To Equity Upon Exercise FairMarketValueOfWarrantsTransferredToEquityUponExercise	2103000
CY2016	nby	Fixed Assets Exchanged For Services FixedAssetsExchangedForServices	279000
CY2015	nby	Fixed Assets Exchanged For Services FixedAssetsExchangedForServices
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015Q4	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	5
CY2015Q4	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	5
CY2016Q4	nby	Accrued Liabilities Research And Development Current AccruedLiabilitiesResearchAndDevelopmentCurrent	2000
CY2015Q4	nby	Accrued Liabilities Research And Development Current AccruedLiabilitiesResearchAndDevelopmentCurrent	394000
CY2016Q3	nby	Area Of Property In Sublease Agreement AreaOfPropertyInSubleaseAgreement	16465
	nby	Class Of Warrant Or Right Exercise Price Discount From Market Price ClassOfWarrantOrRightExercisePriceDiscountFromMarketPrice	0.16
CY2014	nby	Class Of Warrant Or Right Forfeited During Period ClassOfWarrantOrRightForfeitedDuringPeriod	50
CY2015	nby	Class Of Warrant Or Right Forfeited During Period ClassOfWarrantOrRightForfeitedDuringPeriod	56
CY2016	nby	Class Of Warrant Or Right Forfeited During Period ClassOfWarrantOrRightForfeitedDuringPeriod	3
CY2014	nby	Class Of Warrant Or Right Forfeited During Period Exercise Price ClassOfWarrantOrRightForfeitedDuringPeriodExercisePrice	68750
CY2015	nby	Class Of Warrant Or Right Forfeited During Period Exercise Price ClassOfWarrantOrRightForfeitedDuringPeriodExercisePrice	39000
CY2016	nby	Class Of Warrant Or Right Forfeited During Period Exercise Price ClassOfWarrantOrRightForfeitedDuringPeriodExercisePrice	78130
CY2014	nby	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	55
CY2015	nby	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	1317
CY2016	nby	Class Of Warrant Or Right Issued During Period ClassOfWarrantOrRightIssuedDuringPeriod	3087
CY2014	nby	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	39000
CY2015	nby	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	7400
CY2016	nby	Class Of Warrant Or Right Issued During Period Exercise Price ClassOfWarrantOrRightIssuedDuringPeriodExercisePrice	1910
CY2016	nby	Income Tax Reconciliation Revaluation Of Warrant Liability IncomeTaxReconciliationRevaluationOfWarrantLiability	806000
CY2015	nby	Income Tax Reconciliation Revaluation Of Warrant Liability IncomeTaxReconciliationRevaluationOfWarrantLiability	-731000
CY2014	nby	Income Tax Reconciliation Revaluation Of Warrant Liability IncomeTaxReconciliationRevaluationOfWarrantLiability	-565000
CY2016	nby	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	327000
CY2015	nby	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	17000
CY2014	nby	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	36000
CY2015	nby	Issuance Of Stock And Warrants During The Period Value IssuanceOfStockAndWarrantsDuringThePeriodValue	11518000
CY2016	nby	Issuance Of Stock And Warrants During The Period Value IssuanceOfStockAndWarrantsDuringThePeriodValue	7429000
CY2012Q1	nby	Minimum Common Stock Closing Bid Price Per Share MinimumCommonStockClosingBidPricePerShare	66.50
CY2016	nby	Note Receivable Impairment NoteReceivableImpairment	91000
CY2015	nby	Note Receivable Impairment NoteReceivableImpairment
CY2014	nby	Note Receivable Impairment NoteReceivableImpairment
CY2007Q3	nby	Number Of Subsidiaries NumberOfSubsidiaries	2
CY2016Q4	nby	Prepaid Outsourced Sales Team PrepaidOutsourcedSalesTeam	606000
CY2015Q4	nby	Prepaid Outsourced Sales Team PrepaidOutsourcedSalesTeam
CY2016Q4	nby	Prepaid Research And Development Services PrepaidResearchAndDevelopmentServices	123000
CY2015Q4	nby	Prepaid Research And Development Services PrepaidResearchAndDevelopmentServices
CY2016Q4	nby	Prepaid Sales Rebate PrepaidSalesRebate	658000
CY2015Q4	nby	Prepaid Sales Rebate PrepaidSalesRebate
CY2015Q2	nby	Private Placement Commission Percentage PrivatePlacementCommissionPercentage	0.06
CY2016Q1	nby	Private Placement Commission Percentage PrivatePlacementCommissionPercentage	0.06
CY2016Q2	nby	Private Placement Commission Percentage PrivatePlacementCommissionPercentage	0.06
CY2016	nby	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	7429000
CY2015	nby	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	1250000
CY2014	nby	Proceeds From Exercise Of Options And Warrants ProceedsFromExerciseOfOptionsAndWarrants	34000
CY2016Q4	nby	Rent Receivable RentReceivable	165000
CY2015Q4	nby	Rent Receivable RentReceivable
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Number SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableNumber	402000
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageExercisePrice	22.45
CY2016	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Exercisable Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsExercisableWeightedAverageRemainingContractualTerm	P6Y219D
CY2013Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	287000
CY2014Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	323000
CY2015Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	388000
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstanding	1489000
CY2013Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	42
CY2014Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	38.25
CY2015Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	32.03
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsOutstandingWeightedAverageExercisePrice	8.38
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	691000
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Number SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingNumber	1466000
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	8.45
CY2016	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P8Y219D
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested In Period SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriod	402000
CY2016Q4	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested In Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedInPeriodWeightedAverageGrantDateFairValue	22.45
CY2016	nby	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options And Options Vested Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAndOptionsVestedWeightedAverageRemainingContractualTerm	P6Y219D
CY2016	nby	Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees	173000
CY2015	nby	Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees
CY2014	nby	Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Employees StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToEmployees
CY2016	nby	Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees	133000
CY2015	nby	Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees
CY2014	nby	Stockbased Compensation Expense For Issuance Of Restricted Stock Units To Non Employees StockbasedCompensationExpenseForIssuanceOfRestrictedStockUnitsToNonEmployees
CY2014Q1	nby	Units Issued During Period UnitsIssuedDuringPeriod	224000
CY2014Q1	nby	Warrant Date Of Issuance Of Term WarrantDateOfIssuanceOfTerm	P1Y180D
CY2015Q4	nby	Warrant Expiration Term WarrantExpirationTerm	P5Y
CY2015Q4	nby	Warrant Expiration Term WarrantExpirationTerm	P5Y
CY2016	nby	Warrant Liability Transferred To From Equity WarrantLiabilityTransferredToFromEquity	2103000
CY2015	nby	Warrant Liability Transferred To From Equity WarrantLiabilityTransferredToFromEquity	-2175000
CY2014	nby	Warrant Liability Transferred To From Equity WarrantLiabilityTransferredToFromEquity
CY2016	nby	Warrant Modifications WarrantModifications	270000
CY2016Q3	nby	Warrants Exercised Commission Paid WarrantsExercisedCommissionPaid	338000
CY2016Q4	nby	Warrants Exercised Commission Paid WarrantsExercisedCommissionPaid	32000
CY2016Q3	nby	Warrants Exercised Commission Percentage WarrantsExercisedCommissionPercentage	0.06
CY2016Q4	nby	Warrants Exercised Commission Percentage WarrantsExercisedCommissionPercentage	0.06
CY2016	nby	Warrants Exercised Weighted Average Exercise Price WarrantsExercisedWeightedAverageExercisePrice	1950
CY2014Q1	nby	Warrants Per Unit WarrantsPerUnit	1
CY2016Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	2120000
CY2015Q4	us-gaap	Accounts Notes And Loans Receivable Net Current AccountsNotesAndLoansReceivableNetCurrent	536000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	455000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2483000
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	75000
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent
CY2016Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	75000
CY2015Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	0
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1801000
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1980000
CY2016Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	166000
CY2015Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	150000
CY2016Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	333000
CY2015Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	149000
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1702000
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	110619000
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85387000
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	853000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1194000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1316000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1751000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1382000
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1042000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	10000
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	40000
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	240000000
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15269000
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3486000
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15269000
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3486000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	153000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	35000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13151000
CY2015Q4	us-gaap	Assets Assets	5077000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	14471000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	4527000
CY2016Q4	us-gaap	Assets Assets	15381000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2385000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5429000
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10500000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9512000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	7127000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3044000
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5071000
CY2011Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	33.25
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	39
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	19.50
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.15
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	43000
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	35230
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5190
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1810
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	6.25
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	56000
CY2016Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3613284
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	363523
CY2016Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2039530
CY2013Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	192
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	197
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1458
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	565
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18973000
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	170000
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1986000
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2248000
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	829000
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	954000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38677000
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35031000
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15179000
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentrations of Credit Risk, Major Partners and Customers, and Suppliers</div></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> highly-rated, major financial institutions in the United States.</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Deposits in these banks <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> exceed the amount of federal insurance provided on such deposits. The Company does not believe it is exposed to significant credit risk due to the financial position of the financial institutions in which these deposits are held. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the years ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> revenues were derived primarily from sales of Avenova directly to doctors through the Company’s webstore and to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> major distribution partners. During the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> revenues were derived primarily from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> collaboration partner, service revenues and sales of NeutroPhase. </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 14.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> revenues from our major distribution or collaboration partners greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> are as follows:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"></div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 98%; MARGIN-RIGHT: 2%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="10"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Year Ended December 31, </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 55%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Major distribution or collaboration partner </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2016</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Distributer A</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Distributer B</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Distributer C</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Collaborator D</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 14.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Not greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 14.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> accounts receivable from our major distribution or collaboration partners greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> are as follows:</div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 14.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 95%; MARGIN-RIGHT: 5%; TEXT-INDENT: 0px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Year Ended December 31, </div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 68%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Major distribution or collaboration partner</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2016</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Distributer A</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Distributer B</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-weight: bold;"> </div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-weight: bold;"></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"><div style="display: inline; font-weight: bold;"> </div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> <div style=" MARGIN-BOTTOM: 0pt; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Distributer C</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"> </td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 13%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">%</div></div></td> </tr> </table> </div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 14.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt 14.4pt 0pt 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">*Not greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Company relies on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party sole source manufacturers to produce its finished goods. The Company does not have any manufacturing facilities and intends to continue to rely on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties for the supply of finished goods. Third party manufacturers <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may</div> not be able to meet the Company’s needs with respect to timing, quantity or quality.</div></div></div></div></div></div></div></div></div>
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	312500
CY2014	us-gaap	Contracts Revenue ContractsRevenue	625000
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2464000
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1261000
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	486000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2000
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2000
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	2000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32000
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	28000
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	327000
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	189000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2067000
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-818000
CY2016	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	31000
CY2015	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	123000
CY2014	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	44000
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2162000
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1655000
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-252000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1585000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	299000
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-555000
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34902000
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31464000
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	765000
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	652000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1894000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1558000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	287000
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	403000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	38645000
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35003000
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	32000
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	28000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	114000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	164000
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	232000
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.40
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.82
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.65
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.40
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.82
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-7.65
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.40
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.82
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.65
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	763000
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	414000
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1500000
CY2014Q1	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	470000
CY2015Q1	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	200000
CY2015Q4	us-gaap	Expense Related To Distribution Or Servicing And Underwriting Fees ExpenseRelatedToDistributionOrServicingAndUnderwritingFees	400000
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	270000
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants
CY2014	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants
CY2012Q1	us-gaap	Fees And Commissions Other FeesAndCommissionsOther	312500
CY2016	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	219000
CY2015	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	1000
CY2014	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	54000
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7235000
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8006000
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6235000
CY2016	us-gaap	Gross Profit GrossProfit	9433000
CY2015	us-gaap	Gross Profit GrossProfit	3120000
CY2014	us-gaap	Gross Profit GrossProfit	568000
CY2015	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-13149000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-18971000
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15192000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3641000
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	8101000
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6286000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4471000
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6439000
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5154000
CY2016	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	162000
CY2015	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	90000
CY2014	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	153000
CY2016	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-157000
CY2015	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1060000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1447000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6000
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	553000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-472000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	751000
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	451000
CY2016	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	474000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets
CY2014	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	198000
CY2015	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities
CY2014	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1470000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-402000
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-102000
CY2016	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable	87000
CY2015	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable
CY2014	us-gaap	Increase Decrease In Property And Other Taxes Payable IncreaseDecreaseInPropertyAndOtherTaxesPayable
CY2016	us-gaap	Interest Paid InterestPaid	51000
CY2015	us-gaap	Interest Paid InterestPaid
CY2014	us-gaap	Interest Paid InterestPaid
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	555000
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	482000
CY2016Q4	us-gaap	Inventory Net InventoryNet	873000
CY2015Q4	us-gaap	Inventory Net InventoryNet	1345000
CY2016Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	514000
CY2015Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	660000
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	196000
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	45000
CY2016Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	248000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	938000
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1008000
CY2014	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1045000
CY2015Q4	us-gaap	Other Assets Current OtherAssetsCurrent	261000
CY2016Q4	us-gaap	Liabilities Liabilities	8280000
CY2015Q4	us-gaap	Liabilities Liabilities	10175000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15381000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5077000
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4323000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4633000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	19422000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	15601000
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7386000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-160000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-86000
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2598000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12135000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18559000
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15055000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-13151000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-18973000
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-15194000
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	60000
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
CY2011Q3	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1	139520
CY2014Q1	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	211000
CY2016Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent
CY2015Q4	us-gaap	Notes Payable Related Parties Noncurrent NotesPayableRelatedPartiesNoncurrent	1655000
CY2015	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2016	us-gaap	Operating Expenses OperatingExpenses	20415000
CY2015	us-gaap	Operating Expenses OperatingExpenses	24257000
CY2014	us-gaap	Operating Expenses OperatingExpenses	17472000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-10982000
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-21137000
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-16904000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4725000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	987000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	438000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1026000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1116000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1083000
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	75000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	212000
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	232000
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	294000
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	198000
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent
CY2016	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-2099000
CY2015	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	2149000
CY2014	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	1664000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-68000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	539000
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	155000
CY2016	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
CY2015	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
CY2014	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	15000
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17000
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48000
CY2016	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	280000
CY2015	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	235000
CY2014	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	370000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	160000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	123000
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68000
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments
CY2014	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	4012000
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1966000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	261000
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1966000
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	261000
CY2016Q4	us-gaap	Prepaid Rent PrepaidRent	120000
CY2015Q4	us-gaap	Prepaid Rent PrepaidRent
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y109D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y73D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y255D
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	4381000
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	1054000
CY2016	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Reclassifications</div></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not change total assets, total liabilities, or total stockholders’ equity. Additionally, prior period amounts in the accompanying consolidated statement of operations and comprehensive loss and have been reclassified to conform to current period presentation. The reclassifications did not change the net loss or loss per share</div></div></div></div></div></div></div></div></div>
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6700000
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4700000
CY2015Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1900000
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13648000
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11519000
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	227000
CY2016	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1365000
CY2015	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1655000
CY2014	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt
CY2016Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	11800000
CY2016Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	11800000
CY2016	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity
CY2015	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1177000
CY2014	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	7125000
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	37000
CY2014	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	128000
CY2016	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments
CY2015	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments
CY2014	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	6550000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4000
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised
CY2016Q3	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	6600000
CY2016Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	900000
CY2016	us-gaap	Profit Loss ProfitLoss	-13151000
CY2015	us-gaap	Profit Loss ProfitLoss	-18973000
CY2014	us-gaap	Profit Loss ProfitLoss	-15194000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	520000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2097000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	371000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	395000
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y219D
CY2016	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses
CY2015	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses
CY2014	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-40000
CY2016	us-gaap	Repayments Of Debt RepaymentsOfDebt	3020000
CY2015	us-gaap	Repayments Of Debt RepaymentsOfDebt
CY2014	us-gaap	Repayments Of Debt RepaymentsOfDebt
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1371000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5728000
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9483000
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-103671000
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-90520000
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	30
CY2015Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	11617000
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4146000
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	684000
CY2016	us-gaap	Sales Revenue Net SalesRevenueNet	11897000
CY2015	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	188000
CY2016	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	269000
CY2015	us-gaap	Stock Issued1 StockIssued1	63000
CY2014	us-gaap	Stock Issued1 StockIssued1	7000
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	11809000
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10523000
CY2014	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1754000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P2Y7D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	32000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	29000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	28000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	116000
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	36.50
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	30.58
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	28.27
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	68000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	85000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1227000
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	422000
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	702000
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	22.50
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	11.20
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.74
CY2014	us-gaap	Share Based Goods And Nonemployee Services Transaction Stockholders Equity ShareBasedGoodsAndNonemployeeServicesTransactionStockholdersEquity	189000
CY2015	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	8101000
CY2014	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	6286000
CY2016Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1446000
CY2015Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1450000
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9408000
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2784000
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	62000
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	34000
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7101000
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	0
CY2015Q4	us-gaap	Short Term Investments ShortTermInvestments	0
CY2016	us-gaap	Stock Issued1 StockIssued1	8000
CY2015Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	435746
CY2015Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	492000
CY2016Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1518567
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2000
CY2014	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	28000
CY2015	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	63000
CY2016	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	8000
CY2016Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2800000
CY2014	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	77000
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5098000
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	8516000
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1848000
CY2016Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	250000
CY2015Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	790000
CY2016	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	70000
CY2015	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges
CY2014	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	957000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	811000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	974000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	17000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	76000
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"> </div></div> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization period for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div></div>
CY2016	us-gaap	Valuation Allowances And Reserves Period Increase Decrease ValuationAllowancesAndReservesPeriodIncreaseDecrease	3642000
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1985000
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9408000
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2784000
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1985000
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9408000
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2784000
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1985000

Files In Submission

Name	View Source	Status
0001437749-17-005131-index-headers.html	Edgar Link	pending
0001437749-17-005131-index.html	Edgar Link	pending
0001437749-17-005131.txt	Edgar Link	pending
0001437749-17-005131-xbrl.zip	Edgar Link	pending
a1.jpg	Edgar Link	pending
ex10-7.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
ex4-2.htm	Edgar Link	pending
ex4-3.htm	Edgar Link	pending
ex4-5.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nby-20161231.xml	Edgar Link	completed
nby-20161231.xsd	Edgar Link	pending
nby-20161231_cal.xml	Edgar Link	unprocessable
nby-20161231_def.xml	Edgar Link	unprocessable
nby-20161231_lab.xml	Edgar Link	unprocessable
nby-20161231_pre.xml	Edgar Link	unprocessable
nby20161231_10k.htm	Edgar Link	pending
nby20161231_10kimg005.gif	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby

2015 Q4 Form 10-K Financial Statement

#000143774917005131 Filed on March 23, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY NovaBay Pharmaceuticals, Inc. Stock $nby

2015 Q4 Form 10-K Financial Statement

#000143774917005131 Filed on March 23, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBY
NovaBay Pharmaceuticals, Inc. Stock $nby